Who Paid My Doc
Patricia Gerber
Nurse Practitioner Rochester, MN Nurse Practitioner
NPI 1285008649 CMS profile 10548226
200 1St St Sw, Rochester, MN 55905
General payments
$495
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Patricia Gerber of Rochester, MN is reported in the CMS Open Payments database as having received $495 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 57th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $495 | 1 |
Beside peers
- Patricia Gerber
- Nurse Practitioner median
- Middle half of Nurse Practitioner
- National median
In program year 2025, general payments to Patricia Gerber were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.
Show as a table
| Year | Patricia Gerber | Nurse Practitioner median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $50 | $22–$97 | $163 |
| 2020 | $0 | $40 | $16–$108 | $114 |
| 2021 | $0 | $135 | $40–$426 | $132 |
| 2022 | $495 | $152 | $48–$470 | $149 |
| 2023 | $0 | $166 | $54–$529 | $160 |
| 2024 | $0 | $173 | $55–$556 | $164 |
| 2025 | $0 | $174 | $55–$557 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
105
Drug cost
$209,976
Branded share of claims
36.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Venclexta Venetoclax | Brand | 15 | $209,141 | |
| Acyclovir | Generic | 44 | $661 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 23 | $98 | |
| Prednisone | Generic | 23 | $75 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 51 billing codesPaid by Medicare
$631,081
Medicare patients
426
Services billed
60,267
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 60% | |
| Arthritis | 47% | |
| Chronic kidney disease | 29% | |
| Diabetes | 23% | |
| Ischemic heart disease | 23% | |
| Osteoporosis | 22% | |
| Atrial fibrillation | 20% | |
| Depression | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 | Office | 33 | 4,370 | $149,041 |
| Injection, romosozumab-aqqg, 1 mg J3111 | Office | 22 | 6,720 | $55,920 |
| Injection, tocilizumab, 1 mg J3262 | Office | 11 | 9,880 | $46,751 |
| Injection, remdesivir, 1 mg J0248 | Office | 53 | 8,600 | $40,109 |
| Injection, infliximab-axxq, biosimilar, (avsola), 10 mg Q5121 | Office | 22 | 2,028 | $39,269 |
| Injection, methylprednisolone sodium succinate, up to 40 mg J2920 | Office | 12 | 13 | $39 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 16 | 169 | $36 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner in Minnesota
Jill Toliver
Nurse Practitioner · Woodbury, MN
Rebecca Suess
Nurse Practitioner · Burnsville, MN
Kelly Young
Nurse Practitioner · Burnsville, MN
Kimberly Thompson
Nurse Practitioner · Rochester, MN
Janet Wilkinson
Nurse Practitioner · Mora, MN
Virginia Clementson
Nurse Practitioner · Eden Prairie, MN
Related records
Nurse Practitioner in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.